Fig. 1
MiR-25-3p induction by CSC and its effect on survival time of individuals with PDAC. a Heatmap of significantly different expression of microRNAs (P < 0.05, fold change > 2 or < 0.5) detected with microRNA array in HPDE6-C7 cells exposed to CSC (100 µg/ml) or equal amount of DMSO as solvent control. The red (higher expression) or green (lower expression) color represents the normalized expression value of indicated microRNAs. b Expression levels of indicated miRNAs in HPDE6-C7 cell exposed to CSC (100 μg/ml) or equal amount of DMSO as vehicle control. Results represent means ± standard derivation (S.D.) from three independent measurements. c The induction of miR-25-3p overexpression in HPDE6-C7, PANC-1, and BXPC-3 cells was in a CSC dose (0, 0.1, 1.0, 10, and 100 µg/ml) dependent manner. Data represent mean ± S.D. from three independent experiments. d Expression levels of indicated miRNAs in non-tumor tissue samples of smokers (N = 67) or nonsmokers (N = 108). Results represent means ± S.D. from three independent measurements. e Aberrant overexpression of miR-25-3p in surgically removed PDAC samples compared with their paired non-tumor tissue samples in two patient groups and combined sample. f–h Kaplan–Meier estimates of survival time in two groups of patients with PDAC and combined sample by different miR-25-3p levels in tumor. The median survival time for individuals with high miR-25-3p levels (≥median) in Guangzhou, Beijing and combined sample was 10.1, 9.0, and 10.1 months compared with 16.6, 16.0, and 17.8 months in those with low miR-25-3p levels (<median), with the hazard ratio and 95% confidence interval (CI) of 2.20 (95% CI, 1.53–3.63), 1.82 (95% CI, 1.15–3.36), and 2.07 (95% CI, 1.50–3.09). i Significant difference in serum miR-25-3p levels among smokers (N = 22) and nonsmoker (N = 23). Data of (e) and (i) are displayed in min to max boxplot. The line in the middle of the box is plotted at the median while the upper and lower hinges indicated 25th and 75th percentiles. Student t tests were used in (a), (b), and (c) (NS, non-significant, *P < 0.05, **P < 0.01, and ***P < 0.001) and Wilcoxon rank-sum tests were used in (d), (e), and (i) (NS, non-significant, **P < 0.01, and ***P < 0.001)
